title: Dopamine and serotonin receptor binding and antipsychotic efficacy.
abstract: The relationship between clinically effective antipsychotic drug dosage and binding affinity to cloned dopamine (DA) and serotonin receptor subtypes was analyzed in an effort to elucidate the contribution of individual receptor subtypes to medication response. Clinically effective dose and binding affinity to D(2) DA receptor were modestly correlated for typical antipsychotic medications (r=0.54, p=0.046), but surprisingly were not correlated for atypical antipsychotics (r=0.41, p=0.31). For typical antipsychotics, a more robust inverse relationship was observed between medication dose and 5-HT(2C) affinity (r=-0.68, p=0.021). The strongest correlation for typical antipsychotics was observed between drug dosage and 5-HT(2C)/D(2) binding affinity ratio (r=-0.81, p=0.003). For atypical antipsychotics, no significant correlations were identified between medication dosage and 5-HT(2C), 5-HT(2A), 5-HT(2C)/D(2), or 5-HT(2A)/D(2) receptor-binding affinities. In contrast, atypical antipsychotic medication dosage was highly correlated with the ratios of D(2) (5-HT(2A)/5-HT(1A)) (r=0.80, p=0.031), and D(2) (5-HT(2C)/5-HT(1A)) (r=0.78, p=0.038) binding affinities. These observations demonstrate an interaction between D(2) and 5-HT(2C) receptor effects contributing to positive symptom response for typical antipsychotic medications, suggesting that signaling through 5-HT(2C) receptors interacts with and improves antipsychotic effects achieved via D(2) receptor blockade. This analysis also demonstrates that, in contrast to typical antipsychotics, therapeutic effects of atypical antipsychotic medications are determined by opposing interactions among three different domains: (1) increasing D(2) DA receptor-binding affinity enhances antipsychotic potency. (2) Increasing 5-HT(2C) and 5-HT(2A) receptor-binding affinities also facilitate antipsychotic efficacy. (3) Increasing 5-HT(1A) receptor-binding affinity, in contrast, reduces antipsychotic efficacy.
authors.affiliation: Psychiatry Service, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH, USA. Neil.Richtand@uc.edu
authors.forename: Neil M
authors.initials: NM
authors.lastname: Richtand
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Welge
authors.forename: Aaron D
authors.initials: AD
authors.lastname: Logue
authors.forename: Paul E
authors.initials: PE
authors.lastname: Keck
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Strakowski
authors.forename: Robert K
authors.initials: RK
authors.lastname: McNamara
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D011485:Protein Binding / Q000187:drug effects; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000378:metabolism; D044348:Receptors, Serotonin, 5-HT2 / Q000187:drug effects* / Q000378:metabolism; D018709:Statistics, Nonparametric
chemical_list: D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D044348:Receptors, Serotonin, 5-HT2